Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Irene Ghobrial, MD, Tiffany Poon, BS, Meghan Rourke, Stacey Chuma, BSN, Janet Kunsman, NP, Ranjit Banwait, Amy Sam, Diane Warren, Kenneth C. Anderson, Paul Richardson, M.D., Ph.D., Steven P. Treon, MD, PhD, Jeffrey Matous, MD

Blood (2010) 116 (21): 3952.

https://doi.org/10.1182/blood.V116.21.3952.3952

Published: 2010

Journal Articles

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Sun-Young Kong, MD, PhD, Sabikun Nahar, Xian-Feng Li, Weihua Song, MD, Yiguo Hu, Umesh Muchhal, John Desjarlais, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 4064.

https://doi.org/10.1182/blood.V116.21.4064.4064

Published: 2010

Journal Articles

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Sun-Young Kong, MD, PhD, Xian-Feng Li, Sabikun Nahar, Weihua Song, MD, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, M.D., Ph.D., Nikhil C. Munshi, MD, Kenneth C. Anderson, Yu-Tzu Tai, PhD

Blood (2010) 116 (21): 3013.

https://doi.org/10.1182/blood.V116.21.3013.3013

Published: 2010

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Fangxin Hong, PhD, Swaminathan Padmanabhan, MD, Ashraf Z. Badros, MD, Meghan Rourke, Renee Leduc, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Edie Weller, PhD, Jeffrey Matous

Blood (2009) 114 (22): 2727.

https://doi.org/10.1182/blood.V114.22.2727.2727

Published: 2009

Journal Articles

Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).

Teru Hideshima, M.D., Ph.D., Constantine S. Mitsiades, MD, PhD, Hiroshi Ikeda, MD, PhD, Dharminder Chauhan, PhD, Noopur Raje, M.D., Gullu Gorgun, PhD, Mariateresa Fulciniti, PhD, Diana Cirstea, MD, Giulia Perron, MD, Loredana Santo, M.D., Ayaka Hideshima, Klaus Podar, MD, MSc, PhD, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Daniel R. Carrasco, MD, PhD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 295.

https://doi.org/10.1182/blood.V114.22.295.295

Published: 2009

Journal Articles

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

Philip L. McCarthy, MD, Kouros Owzar, PhD, Edward A. Stadtmauer, MD, Sergio Giralt, MD, David D Hurd, MD, Hani Hassoun, MD, Craig Hofmeister, MD, Paul Richardson, M.D., Ph.D., Daniel J. Weisdorf, Marcelo C. Pasquini, MD, Vera Hars, PhD, Michael Kelly, B.S., John Postiglione, Susan Sutherland, Kenneth C. Anderson, MD, Charles Linker, MD

Blood (2009) 114 (22): 3416.

https://doi.org/10.1182/blood.V114.22.3416.3416

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Irene M. Ghobrial, M.D., Swaminathan Padmanabhan, Ashraf Z. Badros, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D., Steven Treon, MD, PhD, Jeffrey Matous

Blood (2009) 114 (22): 3752.

https://doi.org/10.1182/blood.V114.22.3752.3752

Published: 2009

Journal Articles

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Yu-Tzu Tai, Ph.D., Kihyun Kim, M.D., Xian-Feng Li, M.S., Mariateresa Fulciniti, Ph.D., Weihua Song, M.D., Sabikun Nahar, B.S., Peter Burger, B.S., Mathew J. Rumizen, Klaus Podar, M.D., Ph.D., Dharminder Chauhan, Ph.D, Teru Hideshima, M.D., Ph.D., Robert L Schlossman, M.D., Ph.D., Nikhil C. Munshi, Paul Richardson, M.D., Ph.D., Ann Clark, Ph.D., Janet Ogden, Ph.D., Goutopoulos Andreas, Ph.D., Luca Rastelli, Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 3848.

https://doi.org/10.1182/blood.V114.22.3848.3848

Published: 2009

Journal Articles

Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.

Blood (2009) 114 (22): 783.

https://doi.org/10.1182/blood.V114.22.783.783

Published: 2009

Journal Articles

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Irene M. Ghobrial, M.D., Ravi Vij, MD, Nikhil C. Munshi, Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Erica L. Campagnaro, MD, Renee Leduc, Meghan Rourke, Stacey Chuma, Janet Kunsman, NP, Akari M. Dollard, Diane Warren, Brianna Harris, Amy Sam, Kenneth C. Anderson, MD, Paul Richardson, M.D., Ph.D.

Blood (2009) 114 (22): 748.

https://doi.org/10.1182/blood.V114.22.748.748

Published: 2009

Journal Articles

Evolution of Genomic Changes and Their Significance in Myeloma.

Masood A Shammas, PhD, Herve Loiseau, Cheng Li, Ph.D, Leutz Buon, Samir B Amin, MBBS, Parantu Shah, PhD, King Ben, MD, Mariateresa Fulciniti, yu-Tzu Thai, PhD, Paul Richardson, M.D., Ph.D., Stephane Minvielle, Ph.D, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2009) 114 (22): 605.

https://doi.org/10.1182/blood.V114.22.605.605

Published: 2009

Journal Articles

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

Yu-Tzu Tai, Ph.D., Michel de Weers, Ph.D., Xian-Feng Li, MS, Weihua Song, MD, Sabikun Nahar, B.S., Joost M Bakker, Tom Vink, Daniëlle Jacobs, Lukas Oomen, Wim K Bleeker, Nikhil C. Munshi, MD, Jan G. J. van de Winkel, PhD, Paul W. H. I. Parren, PhD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 608.

https://doi.org/10.1182/blood.V114.22.608.608

Published: 2009

Journal Articles

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

Yu-Tzu Tai, Ph.D., Umesh Muchhal, Ph.D., Xian-Feng Li, MS, Sabikun Nahar, B.S., Weihua Song, MD, Holly Horton, Ph.D, Hanh Nguyen, Sher Karki, John Desjarlais, Nikhil C. Munshi, MD, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD

Blood (2009) 114 (22): 609.

https://doi.org/10.1182/blood.V114.22.609.609

Published: 2009

Journal Articles

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Blood (2009) 114 (22): 587.

https://doi.org/10.1182/blood.V114.22.587.587

Published: 2009

Journal Articles

Lack of Response to Vaccination in MGUS and Stable Myeloma.

Rao H Prabhala, PhD, Yvonne A Efebera, MD, Saem Lee, Andrew J Han, Dheeraj Pelluru, Puru Nanjappa, MS, Samir Amin, Christine Pai, Irene Ghobrial, M.D., Robert L Schlossman, M.D., Ph.D., Jacob Laubach, Mariateresa Fulciniti, Paul Richardson, M.D., Ph.D., Kenneth C. Anderson, MD, Nikhil C. Munshi, MD

Blood (2009) 114 (22): 1852.

https://doi.org/10.1182/blood.V114.22.1852.1852

Published: 2009

Journal Articles

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Blood (2009) 114 (22): 1869.

https://doi.org/10.1182/blood.V114.22.1869.1869

Published: 2009

Journal Articles

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Blood (2009) 114 (22): 2878.

https://doi.org/10.1182/blood.V114.22.2878.2878

Published: 2009

Journal Articles

Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.

Nikhil C. Munshi, Herve Avet-Loiseau, MD, PhD, Phil Stephens, PhD, Masood A Shammas, PhD, Cheng Li, Ph.D, Leutz Buon, PhD, Samir B Amin, MBBS, Parantu Shah, PhD, Benjamin King, MD, Mariateresa Fulciniti, PhD, Jagannath Pal, MBBS, PhD, Yu-Tzu Tai, PhD, Paul Richardson, M.D., Ph.D., Stephane Minvielle, Ph.D, Peter Campbell, MD, Kenneth C. Anderson, MD, Andrew Futreal, PhD

Blood (2009) 114 (22): 2846.

https://doi.org/10.1182/blood.V114.22.2846.2846

Published: 2009

Journal Articles

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Kenji Ishitsuka, M.D., Ph.D, Teru Hideshima, M.D., Ph.D, Makoto Hamasaki, M.D., Ph.D, Raje Noopur, M.D., Ph.D, Kumar Shaji, M.D., Ph.D, Hiromasa Hideshima, Norihiko Shiraishi, Ph.D, Paul Richardson, M.D., Ph.D, Nikhil C. Munshi, M.D., Ph.D, Dharminder Chauhan, Ph.D, Jack Arbiser, M.D., Ph.D, Kenneth C. Anderson, M.D., Ph.D

Blood (2004) 104 (11): 1488.

https://doi.org/10.1182/blood.V104.11.1488.1488

Published: 2004

NARROW

Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia

Lenalidomide Enhances Multiple Myeloma Cytotoxicity Induced by a Novel Fc Domain-Engineered Anti-HM1.24 Monoclonal Antibody with Augmented NK Cell Degranulation

Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.

Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.

Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.

Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.

Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.

Evolution of Genomic Changes and Their Significance in Myeloma.

Daratumumab, a Novel Potent Human Anti-CD38 Monoclonal Antibody, Induces Significant Killing of Human Multiple Myeloma Cells: Therapeutic Implication.

XmAb®5592 Fc-Engineered Humanized Anti-HM1.24 Monoclonal Antibody Has Potent in Vitro and In Vivo Efficacy against Multiple Myeloma.

A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.

Lack of Response to Vaccination in MGUS and Stable Myeloma.

Perifosine in Combination with Bortezomib and Dexamethasone Extends Progression-Free Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezombib: Updated Phase I/II Trial Results.

Natural History of Multiple Myeloma Relapsing After Therapy with IMiDs and Bortezomib: A Multicenter International Myeloma Working Group Study.

Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.

Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only